Centauri Therapeutics Limited

📍 London, United Kingdom👥 22 employees💰 Last funded 2019
Biotechnology Research🌐 centauritherapeutics.com
Website LinkedIn
Centauri Therapeutics Limited is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity"​ in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Centauri Therapeutics Limited?
Centauri Therapeutics Limited has 1 investors on record on gritt.io.
When did Centauri Therapeutics Limited last raise funding?
The most recent investment in Centauri Therapeutics Limited recorded on gritt.io was in 2019.
What industry is Centauri Therapeutics Limited in?
Centauri Therapeutics Limited operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Centauri Therapeutics Limited based?
Centauri Therapeutics Limited is headquartered in London, United Kingdom.